|
Determination of ETD in pharmaceutical preparations using the proposed methods. |
|||||
| Sample |
Recoverya ± SD (%) |
||||
|
|
|||||
| Official method |
Proposed methods |
||||
|
|
|||||
| A |
B |
C |
|||
|
|
|||||
| Napilac capsules (200 mg ETD/Capsule) |
X ± SD |
99.70 ± 1.16 |
98.52 ± 0.79 |
100.65 ± 1.19 |
100.27 ± 0.92 |
| tb |
1.87 |
0.74 |
0.86 |
||
| Fb |
2.17 |
1.05 |
1.60 |
||
| Etodine capsules (300 mg ETD/Capsule) |
X ± SD |
100.50 ± 1.36 |
99.95 ± 0.81 |
100.30 ± 0.96 |
100.04 ± 1.02 |
| tb |
0.78 |
0.27 |
0.61 |
||
| Fb |
2.82 |
2.01 |
1.78 |
||
|
a Average of six determinations. b The theoretical t- and F-values, 2.571 and 6.256, respectively for five degree of freedom at 95% confidence level. | |||||
Gouda and Hassan Chemistry Central Journal 2008 2:7 doi:10.1186/1752-153X-2-7 |
|||||